Integrated Wealth Concepts LLC Makes New Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Integrated Wealth Concepts LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,710 shares of the company's stock, valued at approximately $4,015,000.

A number of other large investors have also modified their holdings of the stock. Norges Bank purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $412,258,000. Flossbach Von Storch SE raised its stake in IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after buying an additional 464,791 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after acquiring an additional 316,048 shares in the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $113,104,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $2.98 during trading hours on Tuesday, hitting $436.97. 718,305 shares of the company were exchanged, compared to its average volume of 635,381. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The company has a market capitalization of $35.41 billion, a PE ratio of 40.95, a PEG ratio of 3.41 and a beta of 1.50. The firm has a fifty day simple moving average of $419.59 and a 200-day simple moving average of $428.50.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a report on Monday, April 14th. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $523.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.